Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome
A legfontosabb adatok
- Hol
- Washington D.C. (Egyesült Államok)A helyszín megnézése
- Fázis
- 2. fázis
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 8 és 12 év között vagy?
Forrás: NCT07784582: ki vehet részt
Helyszínek itt: Egyesült Államok
- Children's National HospitalWashington D.C., Egyesült ÁllamokContact: Kimberly Pitner, MSHS, BSN, RNNo longer taking part
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Children's National Research Institute
- Azonosító
- NCT07784582
- A regiszteradat frissítve
- 2026. augusztus 25.
- Eredeti leírás
This is a research study to find out if treatment with transdermal estradiol patches started between 8 to 11.5 years is safe in girls with Turner syndrome who have ovarian failure and to see whether it may improve performance on two tests of working speed and short-term memory.A teljes eredeti leírásKevesebb
Ultra-low Dose Transdermal Estradiol Therapy in Prepubertal Girls With Turner Syndrome and Primary Ovarian Insufficiency.
This is a research study to find out if treatment with transdermal estradiol patches started between 8 to 11.5 years is safe in girls with Turner syndrome who have ovarian failure and to see whether it may improve performance on two tests of working speed and short-term memory.
Bevonási feltételek: Provision of signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study; Female, aged 8 years up to 11 y and 180 days with karyotype confirmed Turner syndrome; FSH result> 10miu/mL in the past 12 months. Since variability in FSH is not uncommon, a single measure of FSH >10mIU/mL in the past calendar year will be deemed sufficient for inclusion into the study even if repeat measures may be under 10mIU/mL; Ability to take the transdermal estradiol medication and be willing to adhere to the treatment regimen; Ability to complete the primary endpoint testing in English. Non-English speakers may be recruited if the participant is capable of performing the English version of the tests.
Kizáró feltételek: Previous estrogen exposure; Spontaneous thelarche with breast Tanner stage 3 or more, spontaneous menarche or history of abnormal uterine bleeding; Cognitive impairment is severe enough to prevent assessment of the primary outcome measures; Untreated hypothyroidism or celiac disease: Individuals may be recruited if on treatment and stable medication dose in past 3 months; History of any type of malignancy; History of a known clotting disorder/deep venous thrombosis; Subjects known to have Y-chromosome material unless they have undergone gonadectomy and have fully external female genitalia; Any clinically significant abnormality as determined by the principal investigator.